Treatment Approach for Langerhans Cell Histiocytosis

Disease Classification and Risk Stratification

The American College of Physicians recommends classifying disease extent to determine appropriate therapy, with single-system single-site (SS-s) being one organ and one location, and single-system multiple-site (SS-m) being one organ and multiple locations 1

The National Institute of Health recommends histopathologic confirmation with immunohistochemistry, including required stains such as CD163/CD68, S100, CD1a, and Langerin (CD207), to define LCH cells as S100+, CD1a+, and Langerin+ 2, 1
The Mayo Clinic recommends BRAF V600E testing through immunohistochemistry or molecular testing, as this mutation is present in >50% of cases and determines targeted therapy eligibility 2, 3

The American Thoracic Society recommends smoking cessation as the cornerstone and first-line treatment, resulting in clinical improvement in approximately 33% of patients, with mandatory smoking cessation counseling and support 1, 4
The European Respiratory Society recommends monitoring with high-resolution CT showing characteristic peribronchiolar nodular infiltrates with cystic spaces in upper/mid-lung distribution, and monitoring DLCO, which is frequently reduced 1, 4

The American Society of Clinical Oncology recommends systemic chemotherapy, with preferred regimens including cladribine, cytarabine, and vinblastine/prednisone, for multifocal single-system or any multisystem disease 1

The American College of Radiology recommends first response assessment within 4 months of initiating treatment, using 18F-FDG PET-CT for staging and response assessment in multifocal/multisystem disease, and extending surveillance intervals to 6-12 months if disease stabilizes or enters remission 1, 4

The American Academy of Neurology recommends considering CNS involvement, which occurs in 5-10% of LCH cases, and presents with diabetes insipidus, and may require specific attention, including BRAF/MEK inhibitors for LCH-associated neurodegeneration 5

Anterior pituitary deficiencies develop in 70-90% of patients with diabetes insipidus within 5 years, most commonly growth hormone deficiency (40-67%), according to the Mayo Clinic Proceedings 6
Endocrine deficits are permanent and do not resolve with LCH treatment, as reported by the Mayo Clinic Proceedings 6